Key result
Marshall-plan ablation is linked to ~55% lower 12-month AF or AT recurrence vs historical controls.
Why the study?
Data on the effectiveness of the Marshall-plan ablation strategy in repeat procedures with durable pulmonary vein isolation were scarce.
Does the Marshall-plan ablation strategy improve freedom from atrial arrhythmias in patients with recurrent persistent atrial fibrillation and durable pulmonary vein isolation?
Cohort (n=76)
No
Does the Marshall-plan ablation strategy improve freedom from atrial arrhythmias in patients with recurrent persistent atrial fibrillation and durable pulmonary vein isolation?
Hazard Ratio: 0.45 (95% CI 0.22–0.93)
Absolute Event Rate: 68.4% vs 44.7%
p-value: p=0.030
The Marshall-plan ablation strategy, including vein of Marshall ethanol infusion, significantly reduces the recurrence of atrial arrhythmias at 12 months in patients with recurrent persistent AF and durable PVI compared to conventional repeat ablation strategies.
Marshall-plan ablation associated with higher AF/AT freedom; hypothesis-generating pending randomized confirmation.
Background There is evidence that vein of Marshall (VoM) ethanol infusion, as part of a standardized lesion set (Marshall-plan) in persistent atrial fibrillation (AF), reduces atrial arrhythmia recurrence when compared to pulmonary vein isolation (PVI) alone. However, data on the effectiveness of the Marshall-plan in repeat procedures with durable PVI is scarce. Purpose In a single-center prospective cohort setting with historical controls, we evaluated the effectiveness of the Marshall-plan as an ablation strategy in patients with recurrent AF who present with durable PVI at the repeat procedure. Methods Consecutive patients with recurrent persistent AF with durable PVI who received a full Marshall-plan lesion set (posterior mitral line with ethanol infusion of VoM, dome line and cavotricuspid isthmus line) at the repeat procedure were prospectively included. As historical controls, patients with a comparable profile who had undergone repeat ablation at our center prior to the introduction of the Marshall-plan were included. Primary outcome was freedom from AF or atrial tachycardia (AT) at 12 months. Results A total of 38 patients were included in each treatment group. Baseline characteristics were similar across treatment groups (mean age 66.8±9.0 years; 32.9% female; and CHA2DS2-VA of 2 (IQR: 1-3]) except from more prior AF ablations (2 [IQR: 2-3] vs 1 [IQR: 1-2], P<0.001) and longer AF history (12 [IQR: 8-18] vs 8 [IQR: 4-10], years, P=0.002) in the Marshall-plan group. All patients in the Marshall-plan group underwent a complete lesion set with block across all anatomical lines. The most common ablation strategy in the control group was posterior wall isolation (PWI; 44.7%) and anterior mitral line (36.8%). Freedom from AF or AT at 12 months was achieved in 26 (68.4%) patients in the Marshall-plan group vs. 17 (44.7%) in the control group (HR 0.45, 95% CI 0.22-0.93, P=0.030). Conclusion The Marshall-plan lesion set, including ethanol VoM infusion, improved freedom from AF or AT at 12 months in patients with recurrent persistent AF and durable PVI at repeat ablation.
No takes yet. Share an insight, caveat, or question.
Akerstrom et al. (2026) conducted a cohort in Recurrent persistent atrial fibrillation with durable pulmonary vein isolation (n=76). Marshall-plan lesion set (including ethanol infusion of vein of Marshall) vs. Historical controls (repeat ablation prior to Marshall-plan) was evaluated on Freedom from atrial fibrillation (AF) or atrial tachycardia (AT) at 12 months (HR 0.45, 95% CI 0.22-0.93, p=0.030). The Marshall-plan ablation strategy improved freedom from atrial fibrillation or tachycardia at 12 months compared to historical controls (68.4% vs 44.7%; HR 0.45; 95% CI 0.22-0.93; P=0.030).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: